Truxima Hits 20% Share For Teva
Rheumatoid Arthritis Indication Helps Rituximab Biosimilar Gain Ground In US
Teva says the Truxima rituximab biosimilar it sells in the US in partnership with Celltrion has captured a fifth of the market a year after launch, driven in part by its exclusive rheumatoid arthritis indication.
